GEMITERO gemcitabine (as hydrochloride) 1 g powder for injection vial

Land: Australië

Taal: Engels

Bron: Department of Health (Therapeutic Goods Administration)

Werkstoffen:

gemcitabine hydrochloride, Quantity: 1138 mg

Beschikbaar vanaf:

Hetero Australia Pty Ltd

INN (Algemene Internationale Benaming):

Gemcitabine hydrochloride

farmaceutische vorm:

Injection, powder for

Samenstelling:

Excipient Ingredients: mannitol; sodium acetate trihydrate; sodium hydroxide

Toedieningsweg:

Intravenous Infusion

Eenheden in pakket:

1 vial

Prescription-type:

(S4) Prescription Only Medicine

therapeutische indicaties:

Gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is also indicated for patients with 5-FU refractory pancreatic cancer.,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.,Gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Product samenvatting:

Visual Identification: White to off-white lyophilised powder to be reconstituted for intravenous use.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Autorisatie-status:

Licence status A

Autorisatie datum:

2015-03-03